A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

Study Director
Dr. Kiyean Nam
Start Date
8 / 2015
Trial Phase
Phase I
Trial Status
in data analysis
Current Enrollment
Target Enrollment

Experimental: Q203 drug products (10mg and 100mg tablets)

Placebo Comparator: Placebo tablets (same excipients used in Q203 drug products)

Fasting: 10, 30, 50,100, 150, 200, 400, 800 mg/kg

With Food: 100 mg/kg

Developer Associations
Compound Associations